Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.
Chimeric Therapeutics has announced the issuance of up to 124,888,889 new fully paid ordinary shares to Lind Global Fund II, LP, as part of a share subscription agreement. This move aims to facilitate funding previously advanced by Lind, potentially enhancing the company’s financial stability and market operations.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian company specializing in cell therapy, positioning itself as a leader in the biotechnology sector. The company focuses on developing innovative treatments and therapies, with a market emphasis on advanced cell-based solutions.
Average Trading Volume: 2,633,915
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$11.03M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.